Luteal Phase - Clinical Point of View - By Dr Dhorepatil BharatiBharati Dhorepatil
Maintenance of pregnancy
Corpus luteum Progesterone
After ovulation ~ during the early first trimester ~ until placental function established
Removal of the corpus luteum spontaneous pregnancy loss
Ovarian progesterone production implantation & early pregnancy
Role of decreased androgens in the ovarian response to stimulation in older women
Part I: Effects of testosterone (T) on preantral and antral follicles
Part II: How to improve ovarian response ?
Exogenous testosterone
DHEA
Aromatase inhibition (AI)
LH/HCG
Growth hormone (GH) / IGF-I
Why we need to predict?
Hormone defects may cause severe neurological, metabolic or cardiovascular consequences and lead to the early onset of osteoporosis
Psychological Depression
Low levels of self esteem and Life satisfaction
Sexual Dysfunction
Indivisualization of Ovulation Induction - Dr Dhorepatil BharatiBharati Dhorepatil
IVF started to develop fast with the aim of maximizing pregnancy rates per cycle
Higher number of oocytes and thus more embryos
Use of unphysiological high doses of gonadotropins
Time consuming protocols
Higher costs
Patient discomfort
Higher risk of OHSS
Very high risk of multiple gestation
Ovarian reserve tests provide an indirect measure of the cohort of recruitable antral follicles present in the FSH window at the beginning of each menstrual cycle..Functional Ovarian Reserve
Luteal Phase - Clinical Point of View - By Dr Dhorepatil BharatiBharati Dhorepatil
Maintenance of pregnancy
Corpus luteum Progesterone
After ovulation ~ during the early first trimester ~ until placental function established
Removal of the corpus luteum spontaneous pregnancy loss
Ovarian progesterone production implantation & early pregnancy
Role of decreased androgens in the ovarian response to stimulation in older women
Part I: Effects of testosterone (T) on preantral and antral follicles
Part II: How to improve ovarian response ?
Exogenous testosterone
DHEA
Aromatase inhibition (AI)
LH/HCG
Growth hormone (GH) / IGF-I
Why we need to predict?
Hormone defects may cause severe neurological, metabolic or cardiovascular consequences and lead to the early onset of osteoporosis
Psychological Depression
Low levels of self esteem and Life satisfaction
Sexual Dysfunction
Indivisualization of Ovulation Induction - Dr Dhorepatil BharatiBharati Dhorepatil
IVF started to develop fast with the aim of maximizing pregnancy rates per cycle
Higher number of oocytes and thus more embryos
Use of unphysiological high doses of gonadotropins
Time consuming protocols
Higher costs
Patient discomfort
Higher risk of OHSS
Very high risk of multiple gestation
Ovarian reserve tests provide an indirect measure of the cohort of recruitable antral follicles present in the FSH window at the beginning of each menstrual cycle..Functional Ovarian Reserve
Ovulation Induction - Simplified - Dr Dhorepatil BharatiBharati Dhorepatil
What are factors to be considered
Ovarian reserve
Previous ovarian response
Basic hormone profile
Role of FSH & LH
Trigger
Luteal phase support
Pregnancy rate/cycle
Significant increase in live birth rate is found when IUI is done with stimulation compared with IUI in natural cycle in women with Unexplained Infertility .
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil BharatiBharati Dhorepatil
What are important factors to be considered important
Ovarian reserve
Previous ovarian response
Basic hormone profile
Role of LH
Trigger
Luteal phase support
Pregnancy rate/cycle
MONITORING PITUITARY DOWN-REGULATION
If GnRH Agonist is started in the late luteal phase a menstrual bleeding normally indicates that the estrogen is low and FSH can be started.
Blood tests will clearly confirm down-regulation – ovarian/pituitary hormones.
Patient selection and work-up
Ovarian stimulation
Monitoring of follicular growth and endometrial development
Timing of insemination
Number of inseminations
Semen preparation
Insemination procedure
Luteal support
Management of poor ovarian reserve- Dr Parul KatiyarDr Parul Katiyar
Premature ovarian aging or ovarian failure is a major cause of female factor infertility. Dr Parul explains the mechanism of premature ovarian failure and discusses some simple measures to preserve/ regain fertility among women.
Ovulation Induction - Simplified - Dr Dhorepatil BharatiBharati Dhorepatil
What are factors to be considered
Ovarian reserve
Previous ovarian response
Basic hormone profile
Role of FSH & LH
Trigger
Luteal phase support
Pregnancy rate/cycle
Significant increase in live birth rate is found when IUI is done with stimulation compared with IUI in natural cycle in women with Unexplained Infertility .
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil BharatiBharati Dhorepatil
What are important factors to be considered important
Ovarian reserve
Previous ovarian response
Basic hormone profile
Role of LH
Trigger
Luteal phase support
Pregnancy rate/cycle
MONITORING PITUITARY DOWN-REGULATION
If GnRH Agonist is started in the late luteal phase a menstrual bleeding normally indicates that the estrogen is low and FSH can be started.
Blood tests will clearly confirm down-regulation – ovarian/pituitary hormones.
Patient selection and work-up
Ovarian stimulation
Monitoring of follicular growth and endometrial development
Timing of insemination
Number of inseminations
Semen preparation
Insemination procedure
Luteal support
Management of poor ovarian reserve- Dr Parul KatiyarDr Parul Katiyar
Premature ovarian aging or ovarian failure is a major cause of female factor infertility. Dr Parul explains the mechanism of premature ovarian failure and discusses some simple measures to preserve/ regain fertility among women.
Imapct of Thyroid disorder on Reproduction-DrSelim.pdfShahjadaSelim1
Thyroid disorders are the commonest endocrine disorders in all people, though less talked about.
Thyroid disease is the second most common endocrine disorder after diabetes in pregnancy but more common than Diabetes in the community.
Female related infertility accounted for 37% and combined male and female factors for 35% of the causes of infertility.
Female fertility begins to decline many years prior to the onset of menopause despite continued regular ovulatory cycles. Although there is no strict definition of advanced reproductive age in women, infertility becomes more pronounced after the age of 35.
“Inheritance” in images, from Darwin’s “tree of life” to DNA’s iconic crystallography to the epigenetic dynamicsHowever, the script needs to be interpreted and receives meaning only from the interplay with the environment
THE ASSISTED REPRODUCTION TECHNOLOGY REGULATION RULES, 2010
Members of drafting committee11 members
1- Sr Advocate Supreme Court of India
2 – Public Interest Legal Support and Research
3 – Dept of Family Welfare, M of Fam Wel and Research
5 – experts from the field of Reproductive Medicine
Ovarian Drilling Do's & Don'ts - By Dhorepatil BharatiBharati Dhorepatil
Rotterdam Criteria 2003
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group
March 2–3, 2007, Thessaloniki, Greece.
Human Reproduction 2008
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
3. Diagnosis.. Catch them Young
Investigation..Optimize
Management..How long?
Long term consequences..is there enough
evidence?
Practical considerations
4. Inability to conceive after one year with routine (standard, basic)
investigations of infertility showing no abnormality.
(RCOG guidelines,1998;
Randolph,2000)
Diagnosis made only after basic evaluation for infertility fails to
reveal any obvious abnormality
Evidence of ovulation, adequate sperm count and fallopian tubes
patency
30% of patient unable to conceive have unexplained
infertility.
5. Long list of putative & subtle causes of
unexplained infertility
• Many are uncertain
• Many have been found in couples of normal fertility.
• Few are actually treatable (Balen,2003)
6. 1. Abnormal follicle growth
2. Luteinized unruptured follicle
3. Hyper secretion of LH.
4. Hyper secretion of prolactin in the presence of ovulation
5. Reduced growth hormone secretion/sensitivity
6. Cytologic abnormalities in oocytes.
7. Genetic abnormalities in oocytes
8. Antibodies to zona pellucida
10. 1. Abnormal secretion of endometrial proteins
2. Abnormal integrin/adhesion molecule
3. Abnormal T cell & natural killer cell activity.
4. Secretion of embryo toxic factors
5. Abnormalities in uterine perfusion
11. 1. Reduction in motility,acrosome reaction,
oocyte binding & zona penetration
2. Ultra structural abnormalities of head
abnormalities
Dr.Dhorepatil,AICOG 2017,KeyNote
12. 1. Poor quality embryo
2. Reduced progression to blastocyst in vitro
3. Abnormal chromosomal complement- increased
miscarriage rate
13. • UI is a diagnosis of exclusion
• To establish the diagnosis of UI the clinician should
consider the following (Moghissi et al,2000)
Was the infertility evaluation
. complete?
. performed correctly?
. interpreted appropriately?
14. Treatment generally indicated if
duration ≥2 years, or
female is >35 years
the prognosis
worse when duration exceeds 3 years
female >35 years of age (Collins et al.,1995).
15. The prognosis is relatively good even without
therapy, If the duration of infertility <2 years,
unless the female partner is >35 years.
(Bhattacharya et al., 2008; Collins et al., 1995).
AGE in Indian population >30yrs?
16. Fertility problems are frequently followed by early
menopause.
Both are an expression of accelerated ovarian ageing.
The time-interval between the onset of accelerated
decline in fertility and the
menopause is 13 yrs…
Human Reproduction, Vol. 18, No. 3, 644-648, March 2003
Subfertility reflects accelerated ovarian ageing
Medical Center Utrecht, Utrecht, The Netherlands
17. On the basis of a fixed interval of 13 years
between onset of accelerated decline of fertility
(25,000 remaining follicles) and the menopause,
it can be speculated that women who become
menopausal by the age of 45 years, have
experienced an accelerated decline of fertility
around the age of 32.
These women can be classified under a separate
clinical entity, “early ovarian ageing”
18. Epidemiological studies have shown that
10% of women in the general population
become menopausal by the age of 45
(Treloar, 1981; van Noord et al., 1997),
19. A prospective cohort study of 863 women.
female health care workers showed that participants serum AMH
concentrations and AFC levels were significantly associated with their
mothers’ menopausal age category.
To provide an estimate of an individual women’s reproductive age, long-
term follow-up studies are still required.
20. What is the aim ?
To increase the monthly pregnancy rate above the
natural rate of 1.5%- 3%
How?
improve gamete quality
increase gamete number
facilitate gamete interaction
21. When? depends on
1. duration of infertility
2. woman's age /ovarian reserve
3. previous pregnancy history
22. Categories of unexplained infertility (ESHRECapri
Workshop Group, 2004)
† 20% of couples after the initial work-up
Couples with mild male subfertility (20–40%)
50% of those in whom conventional treatments have failed
23. Diminished ovarian reserve, as shown by
Elevated S.FSH level, may be one cause (Cahill et al. 1995; Blacker et al. 1997;
Luborsky et al. 2000) and can result in alterations to other hormonal levels. One
study revealed that 5% of women with unexplained infertility had elevated FSH
levels in the early follicular phase (Rodin et al. 1994).
Changes in LH levels, a low FSH/LH ratio and reduced LH concentration in
follicular fl uid have also been speculated to play a role in unexplained infertility
(Cahill et al. 1995; Omland et al.2001). FSH and LH abnormalities may reflect a
dysfunction on the pituitary-ovarian axis (Leach et al. 1997; Omland et al. 2001).
Both the S.E2 levels in follicular phase and the E2/P ratio have been shown to be
elevated in women with unexplained infertility, suggesting altered folliculogenesis
(Blacker et al. 1997; Leach et al. 1997) and an absent midcycle elevation of the
hormone prolactin, which is present in fertile women (Subramanian et al. 1997).
24. Ovarian reserve tests provide an indirect measure of the cohort of
recruitable antral follicles present in the FSH window at the beginning
of each menstrual cycle..Functional Ovarian Reserve
Fauser and Van Heusden, 1997; McGee and Hsueh, 2000.
Ovarian reserve is a complex clinical phenomenon that is influenced
by
age, genetics and environmental variable
26. 38yrs old pt married since 6mnth,whants to know how much
more time she has to delay her pregagncy? what is her
probability of pregnancy at that time and Now?
Her AFC 6-7 and Her AMH is 2.8ng/ml
28yrs old pt married since 2yrs,whants to know how much
more time she can plan to avoid pregnancy as she has
bright carrier option in near future?
Her AFC 3 and Her AMH is 0.8ng/ml
27. Ovarian endocrinology is dynamic. Years of quiescence
are followed by oscillating secretion until near burnout,
“Ovarian reserve testing” assesses where the ovaries
are within this spectrum. These measures seem to most
clearly relate to oocyte quantity, as multiple other
factors (especially age) meaningfully affect oocyte
quality.
One must always keep in mind that as with all
screening tests, no single result is definitive, since
findings must be interpreted in context.
29. 1. Expectant management
2. IUI
3. Ovarian induction with oral or injectable medications
4. IUI with OI
5. ART
Summary of t/t relies on level I evidence from RCTs.
30. Represents lower extreme of normal distribution of fertility
with no defect present.
Likelihood of pregnancy without treatment is less than that
of fertile couples but greater than zero.
Hull et al. found a cumulative PR over 3 years
50%–80% as a function of female age
30%–80% as a function of infertility duration
31. consumption of not more than one unit of alcohol per day
maternal and paternal smoking
caffeine consumption less then 250mg/day ( 2 cups)
female body mass index ideally in the range 19–30
Knowledge about fertile period
NICE 2012
32. Guzick et al - retrospective review (45
studies) - average cycle fecundity of 1.3% to
4.1% in the untreated groups, which was
lower than most treatment
interventions.
33. Benefit of expectant management in UI
RCT comparing outcome after EM for 6 mths vs
immediate intervention concluded that initial EM for 6
months results in a considerable cost-saving without
jeopardizing the chances of having a child.
36. Overcome a subtle defect in ovulatory function
Increasing the number of eggs
Improve the monthly pregnancy rate by simply increasing the
number of oocytes available for fertilization and implantation.
Increasing the density of motile sperm available to these
eggs
40. 29yr old, BMI 28,AFC 6,AMH 3ng/ml pt with
UI of 5yrs for Ovarian stimulation
What dose to start for IUI or IVF
Score..10…dose for IVF-150units
For
IUI..75units
41. Pt no IGD score No follicles No Eggs retrived
50 3 15-10 10-15
50 4-10 10-15 8- 10
50 10-14 5-7 4-5
50 > 14 2-3 1-2
42. Do not offer oral ovarian stimulation agents (such
as clomifene citrate, anastrozole or letrozole) to
women with unexplained infertility
Inform women with unexplained infertility that
clomifene citrate as a stand-alone treatment does
not increase the chances of a pregnancy or a live
birth
NICE 2012
43. Overall effect of CC treatment is smaller and non
significant
One additional pregnancy in 76 CC cycles compared
with untreated control cycles .
The confidence interval includes infinity.
ASRM 2006
44. There was no evidence that clomiphene citrate was more
effective than no treatment or placebo for live birth or
clinical pregnancy per women when randomised with
IUI
Natural cycle
Without IUI but using hCG.
45. No superiority between letrozole and CC for
inducing ovulation in women with unexplained
infertility before IUI.
Badawy et al Fertil Steril 2009
Barraso et al Fertil Steril 2006
46. CONCLUSIONS
In women with unexplained infertility, ovarian stimulation with
letrozole resulted in a significantly lower frequency of multiple
gestation but also a lower frequency of live birth, as compared
with gonadotropin but not as compared with clomi- phene.
(Funded by the National Institutes of Health and others;
ClinicalTrials.gov number, NCT01044862.)
47. FSH/IUI is no better than expectant management when
the prognosis is good, but has a modest effect with more
than 3 years duration of infertility.
There would be one additional pregnancy for every 11
cycles of FSH/IUI
Guzick et al., 1999
Steures et al., 2006
ESHRE capri 2009
48. Multiple pregnancy rates including higher-order
multiples up to 40% have been reported in large
rétrospective studies (Gleicher et al., 2000; Turet al.,
2001; Fauser et al., 2005).
49. Patients with unexplained infertility, who are
having regular unprotected sexual intercourse do
not routinely offer intrauterine insemination, either
with or without ovarian stimulation
NICE 2012
50. Effect of IUI alone per cycle is small and only marginally
significant
Average difference in pregnancy rates between IUI and
control groups was
7% per couple
3% per cycle
51. A protocol that includes an average of three
IUI cycles led to a statistically significant effect.
The magnitude of the benefit, however, is
modest: one additional pregnancy in 14 IUI
couples (95% CI: 8, 23) compared with control
couples (natural cycle).
52. IUI in a natural cycle with expectant management showed no
evidence of increased live births
Six trials where IUI was compared with TI, both in stimulated
cycles, there was evidence of an increased chance of
pregnancy after IUI (six RCTs, 517 women: OR 1.68, 95% CI
1.13 to 2.50).
bhattacharya et al BJM2009, snick et al HR 2008
53. Prospective, randomized, controlled trial and meta
analysis of the literature.
After COH randomly assigned to, IUI and FSP
patients with unexplained infertility had a statistically
higher pregnancy rate with fallopian sperm perfusion (odds
ratio, 4.1; confidence interval, 1.1–16.4)
54. No of patients who became pregnant
FSP – 27%
IUI – 8%
It may be that the large volume of inseminate
washes out tubal obstructions or some factor
that is deleterious to fertilization
55. Meta-analysis of randomized controlled trials
Double IUI - 13.6% clinical pregnancies
Single IUI - 14.4% clinical pregnancies
There was no significant difference between the single and
double IUI groups in the probability for clinical pregnancy
Polyzos et al 2010, fert ster
56. Advise women with unexplained infertility who are
having regular unprotected sexual intercourse to
try to conceive for a total of 2 years (including up to
1 year before investigation) before IVF will be
considered. [new 2012]
NICE 2012
57. ART Vs Expected Management
Pregnancy rate per woman or couple
associated with a single cycle of IVF was
significantly higher than with expectant
management (P = 0.04).
› Hugh et al (HR 2004)
58.
59. No significant increase in multiple
pregnancies with IVF when compared to
IUI+SO.
However
Effectiveness of IVF relative to expectant
management, clomiphene citrate and IUI
alone remains unproven.
60. Randomized controlled trial
conventional treatment
Three cycles of CC/IUI,
Three cycles of FSH/IUI,
up to six cycles of IVF
If fails
If fails
Acceleraed treatment
Three cycles of CC/IUI,
If fails
up to six cycles of IVF
61. Per cycle pregnancy rates for CC/IUI, FSH/IUI, and IVF were 7.6%, 9.8%,
and 30.7%, respectively.
62. Time (mths) conventional (%) Accelerated (%)
6 31.9 43.2
9 43.8 54.7
12 55.4 65.4
Compared with conventional infertility t/t an accelerated approach to
IVF that starts with CC/IUI, but eliminates gonadotropin/IUI, results in a
shorter time to pregnancy, with fewer treatment cycles, and at a
suggested cost savings
63. Couples should undergo a semen analysis, ovulation testing, assessment
of ovarian reserve, and imaging to assess for tubal and uterine factors
before a diagnosis of unexplained infertility is made.
The principal treatments for unexplained infertility include expectant
observation with timed intercourse and lifestyle changes, clomiphene
citrate and intrauterine insemination (IUI), controlled ovarian
hyperstimulation with IUI, and in vitro fertilization (IVF).
Although expectant management is associated with the lowest cost, it
results in the lowest cycle fecundity rates. It may provide an option for a
couple with unexplained infertility in whom the female partner is young
and the problem of oocyte depletion is not an immediate concern.
64. The most expensive, but also most successful
treatment of unexplained infertility consists of the
spectrum of assisted reproductive technology
including IVF, with or without intracytoplasmic
sperm injection. IVF is the treatment of choice for
unexplained infertility when the less costly, but also
less successful treatment modalities have failed.
The optimal treatment strategy needs to be based
on individual patient characteristics such as age,
treatment efficacy, side-effect profile such as
multiple pregnancy, and cost considerations.
65. Depression or history of depression were significantly
higher in women with unexplained infertility than in the
control group (Meller et al, 2002).
Unexplained infertility: prolonged & mutual agony &
sexual dysfunction.
Recognition of the cause of infertility: acceptance of
childlessness & return to normal sexual behavior.